Arcturus Therapeutics

Arcturus Therapeutics

Arcturus Therapeutics incorporated in 2013 under CEO Joseph Payne, who previously co-founded and ran Arcturus predecessor company, and Chief Scientific Officer Pad Chivukula, a biochemist specializing in nanoparticle engineering. The firm went public in 2019, surfacing on public markets with a platform built around self-amplifying mRNA (sa-mRNA) and LUNAR lipid nanoparticle delivery — a combination designed to achieve longer protein expression at lower doses than conventional mRNA. Government biomedical funders became pivotal backers: the Biomedical Advanced Research and Development Authority (BARDA) and the US Department of Defense committed hundreds of millions for sa-mRNA vaccine programs, most notably the $63.2M contract awarded in 2020 for a COVID-19 vaccine candidate. The development portfolio splits across two axes: infectious disease vaccines and rare disease therapies. On the vaccine side, a sa-mRNA COVID-19 vaccine (ARCT-154) achieved approval in Japan in November 2023, making it the first self-amplifying mRNA product to reach any global market (per the firm, November 2023). The flu vaccine program (ARCT-2138) entered Phase 2 trials in 2024. On the rare disease front, the lead asset targets ornithine transcarbamylase (OTC) deficiency via a partnered mRNA therapeutic with Ultragenyx Pharmaceutical — a compound that advanced into registrational trials. The firm also operates a cystic fibrosis mRNA program and a glycogen storage disease type III candidate. Geographic activity spans the United States, Japan (via Meiji Seika Pharma for ARCT-154), Europe (EMA filings underway), and increasingly the Middle East through inquiries tied to pandemic preparedness stockpiles. The firm employs approximately 200 professionals as of early 2025, primarily based in San Diego. The November 2023 approval of ARCT-154 in Japan stands as the landmark operational event of the past two years — a regulatory first for the sa-mRNA modality that validated the platform's commercial viability. Adjacent structures include the Arcturus-owned manufacturing facility in San Diego, which provides clinical-scale production, and a commercial-scale manufacturing agreement with Catalent (now Novo Holdings). Unlike many peers, Arcturus has not spun out a philanthropic foundation; platform access is structured through tiered pricing and technology transfer agreements rather than a formal global-health nonprofit arm. Arcturus operates as a public biotech, but its structural differentiator is the sa-mRNA mechanism itself. Standard mRNA vaccines trigger fleeting protein expression; the sa-mRNA design encodes its own replication machinery, amplifying the signal inside the host cell. This creates a pharmacodynamic edge — lower doses, potentially fewer boosters — that separates it from Moderna and BioNTech's first-generation platforms. The firm's hybrid model blends traditional institutional biotech funding (public equity, licensing fees from Ultragenyx) with government contract revenue, insulating R&D from the pure venture-capital cycle that governs most privately held platform companies.